Pharmacy Daily | J&J’s fourth quarter

JOHNSON & Johnson has reported fourth-quarter 2011 sales of US$16.3 billion, a year on year increase of 3.9%. In fact 2011 was a good year for J&J all-round, with the company also reporting a 5.6% increase on its full-year sales to US$65 billion. In addition the company reported that whilst its full-year domestic US sales were down by 1.8%, its international sales increased by a healthy 12.4%. Meanwhile worldwide pharmaceutical sales of US$24.4 billion for the full-year 2011 represented an increase of 8.8% versus the prior year with an operational increase of 6.2%. US domestic pharmaceutical sales decreased 1.1% whilst international sales increased 21.3%. J&J partly attributes the dip in US pharma sales to the introduction of generic competition for Levaquin (levofloxacin), adding that the strong performance of newly launched drugs such as Stelara helped to stave off the worst effects of this introduction.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 25 Jan 12
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Jan 12